Update on the subcutaneous administration of rituximab in Canadian cancer centres

  • D. Stewart Tom Baker Cancer Center, University of Calgary
  • J. S. Aucoin Centre hospitalier régional de Trois-Rivières (CHRTR), Université de Montréal
  • T. Crosbie The Ottawa Hospital
  • M. Forman Burnaby Hospital
  • E. Lye Lymphoma Canada
  • A. Christofides IMPACT Medicom Inc
  • A. Mitha Hoffmann-La Roche
Keywords: rituximab, subcutaneous, oncology

Abstract

 

Results of studies comparing subcutaneous (sc) with intravenous (iv) rituximab indicate that the two formulations are comparable in efficacy, but most patients and health care professionals prefer the sc route, commonly because of shorter chair time and reduced risk of infusion-related reactions. Recent Canadian data, including those from the scuba study reported here, support the results of earlier international studies showing a reduction in preparation and administration time with the sc formulation, lower cost of administration, and reduced drug wastage because of the fixed sc dosing. Given the significant time and cost savings of the sc formulation, that formulation is gener­ally preferred over the iv formulation for the treatment of follicular lymphoma, diffuse large B cell lymphoma, and chronic lymphocytic leukemia.


Published
2020-02-28
How to Cite
Stewart, D., Aucoin, J. S., Crosbie, T., Forman, M., Lye, E., Christofides, A., & Mitha, A. (2020). Update on the subcutaneous administration of rituximab in Canadian cancer centres. Current Oncology, 27(2). https://doi.org/10.3747/co.27.6041
Section
Short Communication